Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reports Millions In Unpaid GDUFA Fees

Agency figures reveal a shortfall of more than $20m last year

Executive Summary

The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.

You may also be interested in...

User Fee Delinquencies Rising At US FDA After PDUFA Redesign

Prescription drug user fee "receivables" nearly doubled in FY 2018, but the US FDA is not worried.

Generic Companies Race To Withdraw ANDAs

Industry consolidation may be a reason ANDA withdrawals have increased during GDUFA II.

Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts